Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Real Advances for KRAS Mutation-Positive NSCLC: Dr. Neal Reviews MEK Inhibitor Selumetinib
Author
Howard (Jack) West, MD

Dr. Neal continues his summary of ASCO 2012 highlights with a discussion of KRAS mutation-positive advanced NSCLC, a group that actually represents the largest group of NSCLC patients with a defined molecular marker, but also a group for whom we haven't had enough good answers.  Here, Dr. Neal summarizes the very promising work with the MEK inhibitor selumetinib combined with Taxotere (docetaxel), compared with Taxotere alone, for patients with advanced NSCLC and a KRAS mutation.  While the efficacy looks very favorable, it appears to come with a price of increased side effects that may prove to be prohibitively challenging.  Nevertheless, it qualifies as a potential breakthrough for a very significant subpopulation of patients with advanced NSCLC for whom we haven't had prior breakthroughs.

Below you'll find the video and audio versions of the podcast, along with the transcript and figures for this program. 

Dr. Neal ASCO 2012 LC Highlights Selumetinib KRAS mutn pos Adv NSCLC Audio Podcast

Dr. Neal ASCO 2012 LC Highlights Selumetinib KRAS mutn pos Adv NSCLC Transcript

Dr. Neal ASCO 2012 LC Highlights Selumetinib KRAS mutn pos Adv NSCLC Figs

Dr. Neal will continue with the controversial question of how best to manage a patient with a known EGFR mutation after they have completed potentially curative surgery for early stage lung cancer, describing a study he led.

But for now, the question centers around how much of a problem are side effects.  Here, a potentially useful advance in treatment was associated with a nearly 50% chance of being hospitalized from side effects.  To most oncologists, that's more damage than we can readily accept causing in someone we're treating with a goal of balancing life prolongation with quality of life.  Would most of you favor accepting a promising treatment with a threatening side effect profile, or would you favor waiting until we learn more, optimize how we use the drug, or perhaps find a related drug that might provide the benefit with fewer side effects?

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on
Thank you for sharing
By LeviDrake on
Hi bluesun,I don't know of…
By JanineT GRACE … on